Precigen, Inc. revenue
Precigen, Inc.'s revenue was $9.7m in fiscal 2025, up 146.7% on the year before. Since fiscal 2011 ($8.0m) it has grown at a compound 1.4% a year.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 14 | 24 | 72 | 174 | 191 | 231 | 151 | 91 | 32 | 14 | 27 | 6 | 4 | 10 |
| Growth on the year before | — | +71.9% | +72.5% | +202.7% | +141.4% | +10.0% | +21.0% | −34.5% | −40.0% | −64.7% | −55.4% | +88.6% | −76.9% | −36.9% | +146.7% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Product and Service | $7.9M | ▲ 100.4% |
| Products | $4M | ▲ 841.9% |
| Services | $3.9M | ▲ 11.1% |
| Service Exemplar | $3.9M | ▲ 11.1% |
| Papzimeos | $3.4M | — |
| Product Exemplar | $562,000 | ▲ 33.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Precigen, Inc.'s 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Precigen, Inc. | $22.1m | 43.1% | -38.6% |
| Janux Therapeutics, Inc. | $24.0m | 5367.0% | 45.7% |
| Crispr Therapeutics AG | $25.2m | -34.3% | -47.1% |
| Scynexis Inc | $19.2m | 489.8% | -47.9% |
| Abeona Therapeutics Inc. | $25.5m | -87.7% | 212.0% |
| Celularity Inc | $18.7m | -58.1% | 7.2% |
Compare with peers
- Janux Therapeutics, Inc. revenue
- Crispr Therapeutics AG revenue
- Scynexis Inc revenue
- Abeona Therapeutics Inc. revenue
- Celularity Inc revenue
Head to head: JANX vs PGENCRSP vs PGENPGEN vs SCYX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies